Cochrane · systematic review · CD009361
Colesevelam for type 2 diabetes mellitus
Ooi, CP, Loke, SC · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Colesevelam for type 2 diabetes mellitus
Population: patients with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Morbidity | no estimate extracted | NR | No studies |
Mortality | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Functional outcomes | no estimate extracted | NR | No studies |
Costs | no estimate extracted | NR | No studies |
Adverse events (all adverse events) | RR 1.06 [0.97, 1.15] | 6 studies · 1450 participants | Very low |
HbA1c change from baseline to end point (%) ( | no estimate extracted | 5 studies · 1315 participants | Very low |